Annual report pursuant to Section 13 and 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
$ in Thousands, ₪ in Millions
12 Months Ended
Nov. 30, 2018
USD ($)
Nov. 30, 2017
USD ($)
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (19,104) $ (12,367)
Adjustments required to reconcile net loss to net cash used in operating activities:    
Stock-based compensation 4,364 3,364
Share in losses of associated company 731 1,214
Depreciation and amortization expenses 2,624 2,598
Net gain on remeasurement of previously equity interest in Atvio and CureCell to acquisition date at fair value (4,509) 0
Change in fair value of warrants and embedded derivatives 26 (826)
Change in fair value of convertible bonds 0 (192)
Interest expense accrued on loans and convertible loans (including amortization of beneficial conversion feature) 2,564 1,110
Increase (decrease) in deferred taxes 982 (1,310)
Changes in operating assets and liabilities:    
Decrease (increase) in accounts receivable, net (2,901) 33
Increase in inventory (931) (265)
Increase in other assets (19) (3)
Decrease (increase) in prepaid expenses, other accounts receivable and GPP receivable 380 (107)
Decrease in related parties, net (532) (583)
Decrease in accounts payable (796) (933)
Increase in accrued expenses 428 92
Increase (decrease) in employee and related payables (105) 1,142
Increase in deferred income 1,309 1,044
Increase (decrease) in advance payments and receivables on account of grant (193) 2,156
Net cash used in operating activities (15,682) (3,833)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of property and equipment (5,556) (975)
Investments in associates 0 (2,429)
Long-term bank deposits (15) 0
Increase in loan to JV with a related party (1,000) 0
Acquisition of CureCell, net of cash acquired 58 0
Acquisition of Atvio, net of cash acquired 245 0
Net cash used in investing activities (6,268) (3,404)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Short-term line of credit 0 (21)
Proceeds from issuance of shares and warrants (net of transaction costs) 17,392 5,297
Redeemable non-controlling interest 14,058 2,349
Proceeds from receipts on account of shares to be allotted 2,252 0
Repayment of short and long-term debt (377) (1,108)
Repayment of convertible loans and convertible bonds (177) (4,051)
Proceeds from issuance of convertible loans (net of transaction costs) 1,912 5,899
Net cash provided by financing activities 35,060 8,365
NET CHANGE IN CASH AND CASH EQUIVALENTS 13,110 1,128
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS (173) 1,497
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR 3,519 891
CASH, CASH EQUIVALENTS AND RESTRCITED CASH AT END OF YEAR 16,456 3,519
SUPPLEMENTAL NON-CASH FINANCING ACTIVITY    
Conversion of principal amount and accrued interest of convertible loans and bonds to common stock and warrants 7,511 1,277
Classification of loan receivable into services to be received from CureCell 836 0
Leases of Fixed assets 955 0
Receivable from GPP 6,600 0
SUPPLEMENTAL INFORMATION ON INTEREST PAID IN CASH $ 0 $ 903